Cited by 2,409Glioma Diagnosis and TreatmentMedical Imaging Techniques and ApplicationsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Response criteria for phase II studies of supratentorial malignant glioma.

Macdonald, D R, Cascino, T L, Schold, S C, Cairncross, J G·1990·Journal of Clinical Oncology

DOI 10.1200/jco.1990.8.7.1277

Open this paper in CoChat — free account

Abstract

We suggest "new" response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications. Four response categories are proposed: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Response in this scheme is based on major changes in tumor size on the enhanced computed tomographic (CT) or magnetic resonance imaging (MRI) scan. Scan changes are interpreted in light of steroid use and neurologic findings. We advocate careful patient selection, emphasize pitfalls in the assessment of response, and suggest guidelines to minimize misinterpretations of response.

Integrity signals

Registry

Crossref · 10.1200/jco.1990.8.7.1277

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Successful chemotherapy for recurrent malignant oligodendroglioma
Cairncross, J. G., & Macdonald, D. R. (1988) · Annals of Neurology · doi:10.1002/ana.410230408 · Cited by 345
Self-citation
Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors
Levin, V. A., Crafts, D. C., Norman, D. M., Hoffer, P. B., Spire, J., & Wilson, C. B. (1977) · Journal of neurosurgery · doi:10.3171/jns.1977.47.3.0329 · Cited by 199
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.
Surbone, A., Longo, D. L., Vt, D., Ihde, D. C., Duffey, P. L., Jaffe, E. S., Solomon, D., HUBBARD, S. M., & Young, R. C. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1832 · Cited by 178
Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.
Warr, D. G., McKinney, S., & Tannock, I. F. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.9.1040 · Cited by 151
Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas
Chamberlain, M. C., Murovic, J. A., & Levin, V. A. (1988) · Neurology · doi:10.1212/wnl.38.9.1371 · Cited by 149
Steroid‐induced CT changes in patients with recurrent malignant glioma
Cairncross, J. G., Macdonald, D. R., Pexman, J. H. W., & Ives, F. J. (1988) · Neurology · doi:10.1212/wnl.38.5.724 · Cited by 100
Self-citation
Computerized tomography in the prognosis of malignant cerebral gliomas
Murovic, J. A., Turowski, K., Wilson, C. B., Hoshino, T., & Levin, V. A. (1986) · Journal of neurosurgery · doi:10.3171/jns.1986.65.6.0799 · Cited by 42
Criteria and definitions for response and relapse in children with brain tumors
Zeltzer, P. M., Friedman, H. S., Norris, D. G., & Ragab, A. H. (1985) · Cancer · doi:10.1002/1097-0142(19851001)56:7+ · Cited by 35
Post-Surgical Contrast Enhancement Mimicking Residual Brain Tumour
Cairncross, J. G., Pexman, J. H. W., & Rathbone, M. P. (1985) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046643 · Cited by 33
Self-citation
The accuracy of volumetric measurement of high-grade gliomas
Chisholm, R. A., Stenning, S. P., & Hawkins, T. D. (1989) · Clinical Radiology · doi:10.1016/s0009-9260(89)80007-8 · Cited by 32

Flagged first, then by citations

Show all 11 references

Sorted by citations

Items 701–800 of 1,001

Semiautomated Volumetric Measurement on Postcontrast MR Imaging for Analysis of Recurrent and Residual Disease in Glioblastoma Multiforme
Chow, D. S., Qi, J., Guo, X., Miloushev, V. Z., IWAMOTO, F. M., Bruce, J. N., Lassman, A. B., Schwartz, L. H., Lignelli, A., Zhao, B., et al. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3724 · Cited by 68
Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients
Wang, Y., Pan, L., Sheng, X., Mao, Y. Q., Yao, Y., Wang, E., Zhang, N., & Dai, J. (2012) · European journal of medical research · doi:10.1186/2047-783x-17-25 · Cited by 68
First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response
Taal, W., Dubbink, H. J., Zonnenberg, C. B. L., Zonnenberg, B. A., Postma, T. J., Gijtenbeek, J. M. M., Boogerd, W. J., Groenendijk, F. H., Kros, J. M., Kouwenhoven, M. C. M., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq177 · Cited by 68
[11C]-l-Methionine positron emission tomography in the management of children and young adults with brain tumors
Galldiks, N., Kracht, L., Berthold, F., Miletić, H., Klein, J. C., Herholz, K., Jacobs, A. H., & Heiss, W. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9953-x · Cited by 68
The LUMIERE dataset: Longitudinal Glioblastoma MRI with expert RANO evaluation
Suter, Y., Knecht, U., Valenzuela, W., Notter, M., Hewer, E., Schucht, P., Wiest, R., & Reyes, M. (2022) · Scientific Data · doi:10.1038/s41597-022-01881-7 · Cited by 68
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma
Gilbert, M. R., Yuan, Y., Wu, J., Mendoza, T. R., Vera, E. M., Omuro, A. M. P., Lieberman, F. S., Robins, H. I., Gerstner, E. R., Wu, J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa240 · Cited by 67
Patterns of Failure After Concurrent Bevacizumab and Hypofractionated Stereotactic Radiation Therapy for Recurrent High-Grade Glioma
Shapiro, L., Beal, K. P., Goenka, A., Karimi, S., IWAMOTO, F. M., Yamada, Y. J., Zhang, Z., Lassman, A. B., Abrey, L. E., & Gutin, P. H. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.05.031 · Cited by 67
DENDRITIC CELL VACCINATION IN PATIENTS WITH MALIGNANT GLIOMAS
Vleeschouwer, S. D., Rapp, M., Sorg, R. V., Steiger, H., Stummer, W., Gool, S. V., & Sabel, M. (2006) · Neurosurgery · doi:10.1227/01.neu.0000245595.38957.3e · Cited by 67
Primary CNS Lymphoma in Children and Adolescents: A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)
Abla, O., Weitzman, S. S., Blay, J., O’Neill, B. P., Abrey, L. E., Neuwelt, E. A., Doolittle, N. D., Baehring, J. M., Pradhan, K. R., Martin, S. E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1161 · Cited by 67
Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma
Ellingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox193 · Cited by 67
The Role of Chemotherapy in Recurrent Malignant Gliomas: An Overview
Brandes, A. A., & Fiorentino, M. V. (1996) · Cancer Investigation · doi:10.3109/07357909609076900 · Cited by 67
Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience
Scoccianti, S., Detti, B., Sardaro, A., Iannalfi, A., Meattini, I., Leonulli, B. G., Borghesi, S., Martinelli, F., Bordi, L., Ammannati, F., et al. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283005075 · Cited by 66
Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas
Gerstner, E. R., Sorensen, A. G., Jain, R. K., & Batchelor, T. T. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328318402a · Cited by 66
Radiotherapy Plus Concurrent or Sequential Temozolomide for Glioblastoma in the Elderly: A Meta-Analysis
Yin, A., Zhang, L., Cheng, J., Dong, Y. H., Liu, B.-L., Han, N., & Zhang, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074242 · Cited by 66
Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA)
Ghesquières, H., Ferlay, C., Sebban, C., Pérol, D., Bosly, A., Casasnovas, O., Reman, O., Coiffier, B., Tilly, H., Morel, P., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp529 · Cited by 66
Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors
Scott, B. J., Lee, E. Q., McNamara, M. B., Ryg, P. A., Batchelor, T. T., & Wen, P. Y. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop073 · Cited by 66
Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas
Gessler, F. A., Bernstock, J. D., Braczynski, A. K., Lescher, S., Baumgarten, P., Harter, P. N., Mittelbronn, M. G. A., Wu, T., Seifert, V., & Senft, C. (2018) · Neurosurgery · doi:10.1093/neuros/nyy049 · Cited by 67
Survival in patients with recurrent glioma as a measure of treatment efficacy: Prognostic factors following nitrosourea chemotherapy
Rajan, B., Ross, G., Lim, C. C., Ashley, S., Goode, D., Traish, D., & Brada, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00248-4 · Cited by 66
AIDS-related Central Nervous System Lymphomas
Chamberlain, M. C., & Kormanik, P. A. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006262720665 · Cited by 66
Management-Based Structured Reporting of Posttreatment Glioma Response With the Brain Tumor Reporting and Data System
Weinberg, B. D., Gore, A., Shu, H. G., Olson, J. J., Duszak, R., Voloschin, A. D., & Hoch, M. J. (2018) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2018.01.022 · Cited by 65
Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma
Kurz, S. C., Zan, E., Cordova, C., Troxel, A. B., Barbaro, M., Silverman, J. S., Snuderl, M., Zagzag, D., Kondziolka, D. S., Golfinos, J. G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2533 · Cited by 65
Velocity of Radial Expansion of Contrast-enhancing Gliomas and the Effectiveness of Radiotherapy in Individual Patients: a Proof of Principle
Swanson, K. R., Harpold, H. L. P., Peacock, D. L., Rockne, R. C., Pennington, C., Kilbride, L., Grant, R., Wardlaw, J. M., & Alvord, E. C. (2008) · Clinical Oncology · doi:10.1016/j.clon.2008.01.006 · Cited by 65
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131
Vogelbaum, M. A., Berkey, B. A., Peereboom, D. M., Macdonald, D. R., Giannini, C., Suh, J. H., Jenkins, R. B., Herman, J. G., Brown, P. D., Blumenthal, D. T., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-073 · Cited by 65
Self-citation
A Phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001
Blumenthal, D. T., Rankin, C. J., Stelzer, K. J., Spence, A. M., Sloan, A. E., Moore, D. F., Padula, G. D. A., Schulman, S., Wade, M. L., & Rushing, E. J. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-014-0769-0 · Cited by 65
Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas
Ellingson, B. M., Malkin, M. G., Rand, S. D., LaViolette, P. S., Connelly, J., Mueller, W. M., & Schmainda, K. M. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0293-7 · Cited by 65
Efficacy and toxicity of CyberKnife re-irradiation and “dose dense” temozolomide for recurrent gliomas
Conti, A., Pontoriero, A., Arpa, D., Siragusa, C., Tomasello, C., Romanelli, P., Cardali, S. M., Granata, F., Renzis, C. D., & Tomasello, F. F. (2011) · Acta Neurochirurgica · doi:10.1007/s00701-011-1184-1 · Cited by 65
Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept
de Groot, J., Piao, Y., Tran, H. T., Gilbert, M. R., Wu, H.-K., Liu, J., Bekele, B. N., Cloughesy, T. F., Mehta, M. P., Robins, H. I., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0271 · Cited by 68
Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma
Youssef, G., Rahman, R. M., Bay, C. P., Wang, W., Lim-Fat, M. J., Arnaout, O. M., Bi, W. L., Cagney, D. N., Chang, Y.-S., Cloughesy, T. F., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01579 · Cited by 64
Population-Based Study of Pseudoprogression after Chemoradiotherapy in GBM
Roldán, G. B., Scott, J. N., McIntyre, J. B., Dharmawardene, M., de Robles, P. A., Magliocco, A. M., Yan, E., Parney, I. F., Forsyth, P. A., Cairncross, J. G., et al. (2009) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100008131 · Cited by 64
Self-citation
Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients
Park, C., Kim, J., Yim, S. Y., Lee, A. R., Han, J. H., Kim, C., Park, S., Kim, T., Lee, S., Choi, S. H., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq162 · Cited by 64
All-trans retinoic acid in relapsing malignant gliomas: clinical and radiological stabilization associated with the appearance of intratumoral calcifications
Defer, G., Adle‐Biassette, H., Ricolfi, F., Martin, L., Authier, F., Chomienne, C., Degos, L., & Degos, J. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005701507111 · Cited by 64
European Society for Paediatric Oncology (SIOPE) MRI guidelines for imaging patients with central nervous system tumours
Avula, S., Peet, A. C., Morana, G., Morgan, P. S., Warmuth‐Metz, M., Jaspan, T., & European Society for Paediatric Oncology (SIOPE)-Brain Tumour Imaging Group (2021) · Child s Nervous System · doi:10.1007/s00381-021-05199-4 · Cited by 63
A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy
Møller, S., Grunnet, K., Hansen, S., Schultz, H., Holmberg, M., Mau‐Sørensen, M., Poulsen, H. S., & Lassen, U. (2012) · Acta Oncologica · doi:10.3109/0284186x.2012.681063 · Cited by 63
Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging†
Li, Y., Lupo, J., Parvataneni, R., Lamborn, K. R., Cha, S., Chang, S. M., & Nelson, S. J. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos334 · Cited by 63
Phase II Studies of RMP-7 and Carboplatin in the Treatment of Recurrent High Grade Glioma
Gregor, A., Lind, M., Newman, H., Grant, R., Hadley, D. M., Barton, T., & Osborn, C. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006379332212 · Cited by 63
Chemotherapy for Advanced CNS Ependymoma
Gornet, M., Buckner, J. C., Marks, R. S., Scheithauer, B. W., & Erickson, B. J. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006394407245 · Cited by 63
Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
Lu‐Emerson, C., Norden, A. D., Drappatz, J., Lee, E. Q., Beroukhim, R., Ciampa, A. S., Doherty, L. M., LaFrankie, D. C., Ruland, S. F., & Wen, P. Y. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0489-x · Cited by 62
Drug Review: Safety and Efficacy of Bevacizumab for Glioblastoma and Other Brain Tumors
Narita, Y. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt051 · Cited by 62
Interstitial 125I radiosurgery of supratentorial de novo WHO Grade 2 astrocytoma and oligoastrocytoma in adults
Kreth, F. W., Faist, M., Grau, S. J., & Ostertag, C. B. (2006) · Cancer · doi:10.1002/cncr.21750 · Cited by 62
Bevacizumab and Irinotecan in the Treatment of Recurrent Malignant Gliomas
de Groot, J., & Yung, W. K. A. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e3181867bd6 · Cited by 62
Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma
Chamberlain, M. C., & Johnston, S. K. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9722-2 · Cited by 62
Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases
Kumthekar, P., Grimm, S. A., Avram, M. J., Kaklamani, V., Helenowski, I., RADEMAKER, A. W., Cianfrocca, M. E., Gradishar, W. J., Patel, J. D., Mulcahy, M. F., et al. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1055-0 · Cited by 62
Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme
Francesconi, A. B., Dupre, S., Matos, M., Martin, D., Hughes, B. G. M., Wyld, D., & Lickliter, J. D. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2009.12.009 · Cited by 62
Intraobserver and Interobserver Agreement in Volumetric Assessment of Glioblastoma Multiforme Resection
Kubben, P., Postma, A. A., Kessels, A. G. H., van Overbeeke, J. J., & van Santbrink, H. (2010) · Neurosurgery · doi:10.1227/neu.0b013e3181efbb08 · Cited by 62
Longitudinal MRI evidence for decreased survival among periventricular glioblastoma
Young, G. S., Macklin, E. A., Setayesh, K., Lawson, J. D., Wen, P. Y., Norden, A. D., Drappatz, J., & Kesari, S. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0477-1 · Cited by 62
Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Protein Expression in Patients with Recurrent Glioblastoma Treated with Temozolomide
Nagane, M., Kobayashi, K., Ohnishi, A., Shimizu, S., & Shiokawa, Y. (2007) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hym132 · Cited by 62
Novel diagnostic and therapeutic approaches to malignant glioma
Weller, M. (2011) · Swiss Medical Weekly · doi:10.4414/smw.2011.13210 · Cited by 66
Neuroimaging in Neuro-Oncology
Mechtler, L. L. (2008) · Neurologic Clinics · doi:10.1016/j.ncl.2008.09.015 · Cited by 62
Fractionated Stereotactic Radiotherapy with cis-Platinum Radiosensitization in the Treatment of Recurrent, Progressive, or Persistent Malignant Astrocytoma
Glass, J., Silverman, C. L., Axelrod, R. S., Corn, B. W., & Andrews, D. W. (1997) · American Journal of Clinical Oncology · doi:10.1097/00000421-199706000-00002 · Cited by 62
Recording neurological impairment in clinical trials of glioma
Grant, R., Slattery, J. M. A., Gregor, A., & Whittle, I. R. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01051047 · Cited by 62
Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study
Schlegel, U. S. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.1.118 · Cited by 62
11C-MET PET/CT and Advanced MRI in the Evaluation of Tumor Recurrence in High-Grade Gliomas
D'Souza, M. M., Sharma, R., Jaimini, A., Panwar, P., Saw, S. K., Kaur, P., Mondal, A., Mishra, A. K., & Tripathi, R. P. (2014) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000532 · Cited by 61
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma
Reardon, D. A., Desjardins, A., Rixe, O., Cloughesy, T. F., Alekar, S., Williams, J. H., Li, R., Taylor, C. T., & Lassman, A. B. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00950-1 · Cited by 61
Response Classification Based on a Minimal Model of Glioblastoma Growth Is Prognostic for Clinical Outcomes and Distinguishes Progression from Pseudoprogression
Neal, M. L., Trister, A. D., Ahn, S., Baldock, A. L., Bridge, C. A., Guyman, L. A., Lange, J., Sodt, R., Cloke, T., Lai, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3588 · Cited by 61
Bidimensional Measurements in Brain Tumors: Assessment of Interobserver Variability
Provenzale, J. M., Ison, C., & DeLong, D. M. (2009) · American Journal of Roentgenology · doi:10.2214/ajr.09.2615 · Cited by 61
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients
Reardon, D. A., Conrad, C. A., Cloughesy, T. F., Prados, M. D., Friedman, H. S., Aldape, K., Mischel, P. S., Xia, J., DiLea, C., Huang, J. M., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1854-6 · Cited by 61
Multi‐institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high‐grade gliomas
Balmaceda, C. M., Peereboom, D. M., Pannullo, S. C., Cheung, Y. K., Fisher, P. G., Alavi, J. Β., Sisti, M. B., Chen, J., & Fine, R. L. (2008) · Cancer · doi:10.1002/cncr.23167 · Cited by 61
Prognostic Impact of CD133 mRNA Expression in 48 Glioblastoma Patients Treated with Concomitant Radiochemotherapy: A Prospective Patient Cohort at a Single Institution
Métellus, P., Nanni‐Metellus, I., Delfino, C., Colin, C., Tchogandjian, A., Coulibaly, B., Fina, F., Loundou, A., Barrie, M., Chinot, O. L., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1703-6 · Cited by 61
A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma
Fabrini, M. G., Silvano, G., Lolli, I. R., Perrone, F., Marsella, A., Scotti, V., & Cionini, L. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9739-6 · Cited by 61
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma
Franceschi, E., Stupp, R., van den Bent, M. J., van Herpen, C., Laigle–Donadey, F., Gorlia, T., Hegi, M. E., Lhermitte, B., Strauss, L. C., Allgeier, A., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos256 · Cited by 61
Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation
Wick, W., Steinbach, J. P., Platten, M., Hartmann, C. J., Wenz, F. K., von Deimling, A., Shei, P., MOREAU, V., Stoffregen, C., & Combs, S. E. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not100 · Cited by 61
Phase I study of terameprocol in patients with recurrent high-grade glioma
Grossman, S. A., Ye, X., Peereboom, D. M., Rosenfeld, M. R., Mikkelsen, T., Supko, J. G., & Desideri, S. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nor230 · Cited by 61
Intra-rater variability in low-grade glioma segmentation
Bø, H. K., Solheim, O. S., Jakola, A. S., Kvistad, K.-A., Reinertsen, I., & Berntsen, E. M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2312-9 · Cited by 66
Advanced MRI Techniques in the Monitoring of Treatment of Gliomas
Hyare, H., Thust, S. C., & Rees, J. H. (2017) · Current Treatment Options in Neurology · doi:10.1007/s11940-017-0445-6 · Cited by 61
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
Schiff, D., Jaeckle, K. A., Anderson, S. K., Galanis, E., Giannini, C., Buckner, J. C., Stella, P. J., Flynn, P. J., Erickson, B. J., Schwerkoske, J. F., et al. (2018) · Cancer · doi:10.1002/cncr.31219 · Cited by 62
Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine
Galldiks, N., Dunkl, V., Ceccon, G. S., Tscherpel, C., Stoffels, G., Law, I. G., Henriksen, O. M., Muhic, A., Poulsen, H. S., Steger, J., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4082-4 · Cited by 61
Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response
Roberts, T. A., Hyare, H., Agliardi, G., Hipwell, B., d’Esposito, A., Ianuș, A., Breen‐Norris, J. O., Ramasawmy, R., Taylor, V., Atkinson, D., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65956-4 · Cited by 61
Standard clinical approaches and emerging modalities for glioblastoma imaging
Bernstock, J. D., Gary, S. E., Klinger, N. V., Valdes, P. A., Essayed, W. I., Olsen, H. E., Chagoya, G., Elsayed, G., Yamashita, D., Schuss, P., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac080 · Cited by 67
Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma
Muragaki, Y., Maruyama, T., Iseki, H., Tanaka, M., Shinohara, C., Takakura, K., Tsuboi, K., Yamamoto, T., Matsumura, A., Matsutani, M., et al. (2011) · Journal of neurosurgery · doi:10.3171/2011.4.jns10377 · Cited by 60
Phase II Study of Temozolomide and Concomitant Whole-Brain Radiotherapy in Patients with Brain Metastases from Solid Tumors
Kouvaris, J., Miliadou, A., Kouloulias, V., Kolokouris, D., Balafouta, M., Papacharalampous, X. N., & Vlahos, L. J. (2007) · Oncology Research and Treatment · doi:10.1159/000102557 · Cited by 60
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma
Stupp, R., Pavlidis, N. A., & Jelić, S. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi834 · Cited by 60
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme
Puduvalli, V. K., Giglio, P., Groves, M. D., Hess, K. R., Gilbert, M. R., Mahankali, S., Jackson, E. F., Levin, V. A., Conrad, C. A., Hsu, S. H., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2007-060 · Cited by 60
Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma.
Darlix, A., Baumann, C., Lorgis, V., Ghiringhelli, F., Blonski, M., Chauffert, B., Zouaoui, S., Pinelli, C., Rech, F., Beauchesne, P. D., et al. (2013) · PubMed · Cited by 60
Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide
Chamberlain, M. C. (2001) · Pediatric Neurology · doi:10.1016/s0887-8994(00)00249-6 · Cited by 60
Chemotherapeutic wafers for High Grade Glioma
Hart, M. G., Grant, R., Garside, R., Rogers, G., Somerville, M., & Stein, K. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007294 · Cited by 60
Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning
Suchorska, B., Schüller, U., Biczok, A., Lenski, M., Albert, N. L., Giese, A., Kreth, F.-W., Ertl-Wagner, B., Tonn, J.-C., & Ingrisch, M. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.019 · Cited by 59
Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results
Wismeth, C., Dudel, C., Pascher, C., Paul Ramm, S., Pietsch, T., Hirschmann, B., Reinert, C., Proescholdt, M. A., Rümmele, P., Schuierer, G. R., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0093-0 · Cited by 59
Pseudoprogression in Patients With Glioblastoma Multiforme After Concurrent Radiotherapy and Temozolomide
Topkan, E., Topuk, S., Oymak, E., Parlak, C., & Pehlivan, B. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318210f54a · Cited by 59
Intraarterial chemotherapy and osmotic blood‐brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system
Jahnke, K., Kraemer, D. F., Knight, K. R., Fortin, D., Bell, S. D., Doolittle, N. D., Muldoon, L. L., & Neuwelt, E. A. (2007) · Cancer · doi:10.1002/cncr.23221 · Cited by 59
Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study
Greenspoon, J. N., Sharieff, W., Hirte, H. W., Overholt, A., DeVillers, R., Gunnarsson, Þ., & Whitton, A. C. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s60358 · Cited by 59
Temozolomide in Patients with Glioblastoma at Second Relapse after First Line Nitrosourea-Procarbazine Failure: A Phase II Study
Brandes, A. A., Ermani, M., Basso, U., Paris, M. K., Lumachi, F., Berti, F., Amistà, P., Gardiman, M. P., Iuzzolino, P., Turazzi, S., et al. (2002) · Oncology · doi:10.1159/000065718 · Cited by 59
NOA‐05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri
Glas, M., Bähr, O., Felsberg, J., Rasch, K., Wiewrodt, D., Schabet, M., Simon, M., Urbach, H., Steinbach, J. P., Rieger, J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22478 · Cited by 59
Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study
Gururangan, S., Fangusaro, J., Poussaint, T. Y., Onar‐Thomas, A., Gilbertson, R. J., Vajapeyam, S., Gajjar, A. J., Goldman, S., Friedman, H. S., Packer, R. J., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos213 · Cited by 59
Measuring glioma volumes: A comparison of linear measurement based formulae with the manual image segmentation technique
Madhugiri, V. S., Sreenivasan, S., Sasidharan, G. M., & Kumar, R. V. R. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.153999 · Cited by 59
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide‐refractory glioblastoma multiforme
Chamberlain, M. C., & Tsao-Wei, D. D. (2004) · Cancer · doi:10.1002/cncr.20072 · Cited by 59
Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51
Laack, N. N., Ballman, K. V., Brown, P. B., & O’Neill, B. P. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.03.061 · Cited by 59
Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences
Quach, S., Schmutzer-Sondergeld, M., Schwartz, C., Weller, J., Siller, S., Aumiller, M., Heckl, C., Forbrig, R., Niyazi, M., Egensperger, R., et al. (2021) · Cancers · doi:10.3390/cancers13081767 · Cited by 63
The efficacy of temozolomide for recurrent glioblastoma multiforme
Chen, C., Xu, T., Lu, Y., Chen, J., & Wu, S. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03778.x · Cited by 58
Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma
Korfel, A., Martus, P., Nowrousian, M. R., HOSSFELD, D. K., Kirchen, H., Bruecher, J., Stelljes, M., Birkmann, J., Peschel, C., Pasold, R., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05284.x · Cited by 58
Diffusion-weighted MRI as a biomarker for treatment response in glioma
Schmainda, K. M. (2012) · CNS Oncology · doi:10.2217/cns.12.25 · Cited by 58
Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma
Ellingson, B. M., Kim, E. H., Woodworth, D. C., Marques, H. S., Boxerman, J. L., Safriel, Y. I., McKinstry, R. C., Bokstein, F., Jain, R., Chi, T., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2891 · Cited by 58
A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme
White, E., Bienemann, A. S., Taylor, H., Hopkins, K., Cameron, A. L., & Gill, S. S. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.10.010 · Cited by 60
Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project
Schmainda, K. M., Prah, M. A., Rand, S. D., Liu, Y., Logan, B. R., Muzi, M., Levendovszky, S. R., Da, X., Yen, Y., Kalpathy–Cramer, J., et al. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5675 · Cited by 58
Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma
Franceschi, E., Cavallo, G., Scopece, L., Paioli, A., Pession, A., Magrini, E., Conforti, R., Palmerini, E., Bartolini, S., Rimondini, S., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602105 · Cited by 58
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme
Barrié, M., Couprie, C., Dufour, H., Figarella-Branger, D. F., Muracciole, X., Hoang‐Xuan, K., Braguer, D., Martin, P., Peragut, J. C., Grisoli, F., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi225 · Cited by 58
Brain Tumors
Brandão, L. A., Shiroishi, M. S., & Law, M. (2013) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2013.02.003 · Cited by 57
Estudio observacional retrospectivo sobre la efectividad del ácido 5-aminolevulínico en la cirugía de los gliomas malignos en España (Estudio VISIONA)
Valle, R. D., Slof, J., Galván, J., Arza, C., Romariz, C., & Vidal, C. (2013) · Neurología · doi:10.1016/j.nrl.2013.05.004 · Cited by 57
Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence
Wick, W., Wick, A., Weiler, M., & Weller, M. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0184-0 · Cited by 57
Treatment of newly diagnosed symptomatic pure low‐grade oligodendrogliomas with PCV chemotherapy
Lebrun‐Frénay, C., Fontaine, D., Bourg, V., Ramaioli, A., Chanalet, S., Burel‐Vandenbos, F., Lonjon, M., Fauchon, F., Paquis, P., & Frénay, M. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01675.x · Cited by 57
MicroRNA Expression Signatures Determine Prognosis and Survival in Glioblastoma Multiforme—a Systematic Overview
Henriksen, M., Johnsen, K. B., Andersen, H. H., Pilgaard, L., & Duroux, M. C. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8668-y · Cited by 57

Authors: Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G.
Affiliations: Western University (CA)
ORCID: Cairncross, J G
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 1990-07
Volume: 8
Issue: 7
Pages: 1277-1280
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.1990.8.7.1277
OpenAlex: W1959628099
Cited by: 2,409
References: 11
Citations by year: 2026: 31 · 2025: 21 · 2024: 36 · 2023: 52 · 2022: 53 · 2021: 59 · 2020: 68 · 2019: 75 · 2018: 97 · 2017: 111 · 2016: 125 · 2015: 122 · 2014: 161 · 2013: 186 · 2012: 145
FWCI: 3.90
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: high-grade glioma, supratentorial glioma, response criteria, tumor size measurement, complete response, partial response, stable disease, progressive disease, steroid use, neurologic findings, patient selection, magnetic resonance imaging, computed tomography
MeSH terms: Diagnostic Errors, Drug Evaluation, Glioma, Humans, Magnetic Resonance Imaging, Medical Oncology, Tomography, X-Ray Computed, Supratentorial Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Response criteria for phase II studies of supratentorial malignant glioma.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks